Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Drug Profile

Research programme: TREM-1 targeted therapeutics - Novo Nordisk

Alternative Names: hTREM1-IgG fusion protein - Novo Nordisk; TREM-1 - Novo Nordisk

Latest Information Update: 05 Sep 2014

Price : $50

At a glance

  • Originator BioXell SpA
  • Developer Novo Nordisk
  • Class Proteins
  • Mechanism of Action TREM modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation; Inflammatory bowel diseases; Septic shock

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 30 Dec 2009 Preclinical trials in Septic shock in Denmark (Parenteral)
  • 30 Dec 2009 Preclinical trials in Inflammatory bowel disease in Denmark (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top